Amend KRS 315.010 to define terms; amend KRS 315.020 to require a terminal distributor to designate a responsible practitioner for each permitted location; require the Kentucky Board of Pharmacy to promulgate administrative regulations to establish criteria for a responsible practitioner; permit the board to enter agreements with other states, federal agencies, and entities to exchange information concerning permitting and inspection of pharmacies and terminal distributors; amend KRS 315.035 and 315.0351 to update the name of an approved accreditation agency to National Association of Boards of Pharmacy Digital Pharmacy Accreditation Program; permit the board to consider previous permit compliance and violations of permit applicants; amend KRS 315.121 to require the board to retain jurisdiction to investigate and to take disciplinary action for acts or omissions committed while a person was licensed, permitted, or certified even if the person is no longer licensed, permitted, or certified; amend KRS 315.131 to permit the board to extend temporary emergency suspensions of a license, certificate, or permit for 60 to 180 days; amend KRS 315.191 to prohibit the board from regulating other professions; amend KRS 315.220 to permit the board to enter all licensed or permitted facilities and any facility suspected of operating as a pharmacy, terminal distributor, wholesaler, or manufacturer; establish inspection criteria; permit the board to investigate any location at which it has reasonable cause to suspect a violation is being committed; require cooperation with investigations; create new sections of KRS Chapter 315 to require that on or after January 1, 2027, a permit is required to operate as a terminal distributor of prescription drugs; establish permit requirements for terminal distributors; establish requirements for internet business; allow the board to consider previous permit compliance and violations of permit applicants; allow temporary permit transfer; establish permit exclusions; require the board to promulgate administrative regulations to implement the permit process; establish compounding requirements and prohibitions; require reporting of a serious adverse event to the board within 5 business days; require the board to report violations and inspections to a responsible practitioners' licensing board; require the board to submit a report to the Legislative Research Commission on its inspection and investigation findings by August 1 of each year; permit the board to take action to restrain or enjoin; amend KRS 315.990 to add penalties; amend KRS 194A.800, 217.215, 217.913, and 315.205 to conform; provide that the Act may be cited as Jimmie's Law; EMERGENCY.
Amend KRS 304.17A-163 to modify the definition of "health plan"; require insurers, health plans, private review agents, and pharmacy benefit managers to disclose certain information about step therapy protocols on their website and ensure that the electronic process for requesting and transmitting prior authorization for a drug includes the ability for prescribing providers to electronically transmit a complete request for a step therapy exception; require coverage for a prescription drug on the date the provider submits a step therapy exception request; provide that requirements apply to Medicaid and KCHIP benefits to the extent authorized by federal law; require the Cabinet for Health and Family Services or the Department for Medicaid Services to seek federal approval if it is determined that such approval is necessary; provide authorization from the General Assembly to make changes in the Medicaid program as required under KRS 205.5372(1); provide that the Act applies to policies, certificates, contracts, and plans issued or renewed on or after the effective date of the Act.
Create a new section of Subtitle 17A of KRS Chapter 304 to require health plans to include a generic drug or biosimilar on the plan's formulary under specified circumstances; define terms; establish cost-sharing requirements when a generic drug or biosimilar is required to be placed on the health plan's formulary; prohibit a health plan from imposing any prior authorization, step therapy, or other limitation on coverage for a generic drug or biosimilar required to be placed on the health plan's formulary or imposing any restriction on a pharmacist or pharmacy that makes it more difficult for the insured to obtain coverage or access to the generic drug or biosimilar compared to the reference drug or product; amend KRS 304.17C-125, 164.2871, and 18A.225 to require limited health service benefit plans, self-insured group health plans offered by a state postsecondary education institution, and the state employee health plan to comply with the requirements for generic drugs and biosimilars; direct that the Act applies to health plans issued or renewed on or after January 1, 2027; EFFECTIVE, January 1, 2027.
Amend KRS 304.17A-164 to define terms; prohibit insurers and administrators from requiring insureds to pay cost sharing for a prescription drug that is greater than the cash price; require insurers and administrators to count the amount paid for a covered prescription drug towards the insured's cost-sharing if certain requirements are met; establish requirements for insurers, administrators, and pharmacies for submission of cash price paid by an insured; exempt a state employee health plan from counting certain third-party payments towards the insured's cost-sharing; provide for construction of cost-sharing requirements; amend KRS 304.17C-125, 304.38A-115, 164.2871, and 18A.225 to apply cost-sharing requirements to limited health plans, self-insured state postsecondary education institution employer group health plans, and the state employee health plan; create a new section of KRS Chapter 315 to require pharmacies to comply with cost-sharing requirements; provide that cost-sharing requirements apply to health plans issued or renewed on or after effective date; EFFECTIVE, January 1, 2027.
Create a new section of KRS Chapter 13A to find 201 KAR 9:270 and 201 KAR 20:065 deficient and void; create new sections of KRS Chapters 311, 313, 314, and 315 to establish that the State Board of Medical Licensure, Board of Dentistry, Kentucky Board of Nursing, and Kentucky Board of Pharmacy shall not promulgate administrative regulations that restrict or limit the prescribing, dispensing, or administering of buprenorphine-mono-product, buprenorphine-combined-with-naloxone, or any other Schedule III, IV, or V medication approved by the United States Food and Drug Administration for the treatment of a substance use disorder; EMERGENCY.
Create a new section of KRS Chapter 205 to prohibit the Department for Medicaid Services, any Medicaid managed care organization contracted by the department, and the Medicaid state pharmacy benefit manager from denying coverage for a nonopioid analgesic in favor of opioid analgesic or establishing more restrictive or more extensive utilization controls for nonopioid analgesics than the least restrictive or extensive utilization controls for any opioid or narcotic analgesic; require the Cabinet for Health and Family Services or the Department for Medicaid to seek federal approval if it is determined that such approval is necessary; provide authorization from the General Assembly to make changes to the Medicaid program as required under KRS 205.5372(1).
Amend KRS 205.522 and 205.6485 to require Medicaid and KCHIP to comply with pharmacy reimbursement requirements established in KRS 304.12-237; require the Cabinet for Health and Family Services or the Department for Medicaid to seek federal approval if it is determined that such approval is necessary; provide authorization from the General Assembly to make changes to the Medicaid program as required under KRS 205.5372(1).
Amend KRS 304.17A-164 to define terms; prohibit insurers and administrators from requiring insureds to pay cost sharing for a prescription drug that is greater than the cash price; require insurers and administrators to count the amount paid for a covered prescription drug towards the insured's cost-sharing if certain requirements are met; establish requirements for insurers, administrators, and pharmacies for submission of cash price paid by an insured; exempt a state employee health plan from counting third-party payments unless a cash price was paid that is less than the plan's negotiated price; provide for construction of cost-sharing requirements; amend KRS 304.17C-125, 304.38A-115, 164.2871, and 18A.225 to apply cost-sharing requirements to limited health plans, self-insured state postsecondary education institution employer group health plans, and the state employee health plan; create a new section of KRS Chapter 315 to require pharmacies to comply with cost-sharing requirements; provide that cost-sharing requirements apply to health plans issued or renewed on or after effective date; EFFECTIVE, January 1, 2027.
Amend KRS 304.17A-164 to define and redefine terms; establish cost-sharing requirements for prescription drugs; require rebates to be passed through; establish confidentiality requirements for the rebate information; create a new section of KRS 365.880 to 365.900 to provide that the actual amount of rebates received is a trade secret; provide that compliance with prescription drug cost-sharing and rebate requirements shall not be in violation of the Uniform Trade Secrets Act; amend KRS 304.17C-125, 304.38A-115, 18A.225, and 164.2871 to apply the cost-sharing and rebate requirements for prescription drugs to limited health service benefit plans, limited health service organizations, the state employee health plan, and self-insured employer group health plans provided by the governing board of a state postsecondary education institution; apply provisions to health plans issued or renewed on or after January 1, 2027; EFFECTIVE January 1, 2027.
Amend KRS 304.17A-164 to define and redefine terms; establish cost-sharing requirements for prescription drugs; require rebates to be passed through; establish confidentiality requirements for the rebate information; create a new section of KRS 365.880 to 365.900 to provide that the actual amount of rebates received is a trade secret; provide that compliance with prescription drug cost-sharing and rebate requirements shall not be in violation of the Uniform Trade Secrets Act; amend KRS 304.17C-125, 304.38A-115, 18A.225, and 164.2871 to apply the cost-sharing and rebate requirements for prescription drugs to limited health service benefit plans, limited health service organizations, the state employee health plan, and self-insured employer group health plans provided by the governing board of a state postsecondary education institution; apply provisions to health plans issued or renewed on or after January 1, 2027; EFFECTIVE January 1, 2027.
